NATIONAL TAIWAN UNIVERSITY HOSPITAL

Oneness Biotech and Microbio (Shanghai) announce SNS812, a pan-COVID new drug, achieved statistical significance in Phase 2 trial, demonstrating broad-spectrum efficacy and safety against various virus strains, including JN.1 and high immune-escape variants.